Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics
Our integrative approach highlights phenotype-specific drug targets and FDA-approved candidates to modulate dysfunctional neutrophil responses in sepsis. This strategy supports a precision medicine framework for repurposing existing drugs based on neutrophil functional phenotyping.
Authors
- Salim Merali (ORCID: https://orcid.org/0000-0002-0280-5289)
- Narender Singh (ORCID: https://orcid.org/0000-0002-0332-8592)
- Mohammad F. Kiani (ORCID: https://orcid.org/0000-0003-1533-0179)
- Laurie E. Kilpatrick (ORCID: https://orcid.org/0000-0002-2554-507X)
- Carmen Merali (ORCID: https://orcid.org/0000-0003-4679-710X)
- Balabhaskar Prabhakarpandian
- Qingliang Yang (ORCID: https://orcid.org/0000-0002-4094-9662)
- Jordan C. Langston (ORCID: https://orcid.org/0000-0001-9522-7723)
- Dan Liu (ORCID: https://orcid.org/0000-0003-4341-0010)
- Jennifer L. Fisher (ORCID: https://orcid.org/0000-0002-7944-0505)
Institutions
- Inflammation Research Foundation (US)
- CFD Research Corporation (United States) (US)
- Temple University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1646141
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.50
Funders
- National Institutes of Health